News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CELLECTIS SA And Murinus GmbH Enter Into A License Agreement For The Use Of The Homologous Recombination In Generating Mouse Models


10/19/2005 5:11:23 PM

Cellectis, the rational genome engineering company, and Murinus GmbH announced today they have entered into a non-exclusive license agreement. Cellectis has granted Murinus rights under its patent family relating to the use of homologous recombination for the specific replacement or insertion of a gene in the mouse genome. Through this agreement, Murinus obtained a license under Cellectis patents for developing and selling, in Europe and Middle-East, genetically modified mice for industry and academia. Financial terms and conditions of the agreement were not disclosed.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES